compounding pharmacy glp-1 fda enforcement news today issued 25 warning letters to telehealth companies for false and misleading claims about compounded products. Unlike FDA-approved drugs, these products have not been proven to be safe, effective, or of Out of Shortage, Into Controversy:

Consult with one of our licensed, medical providers through a text-based telehealth visit

BPC-157 : BPC-157 10

Poor quality products can contain contaminants, incorrect concentrations, or degraded peptide that is ineffective at best and harmful at worst

Elevated hsCRP is an independent cardiovascular risk factor, and its reduction is considered a surrogate marker for improved cardiovascular outcomes Systolic blood pressure clinically meaningful reductions These improvements are consistent with but in several cases exceed the cardiometabolic benefits observed with semaglutide and tirzepatide in their respective Phase III programs

BPC-157 is a signaling peptide that upregulates growth factors involved in tissue repair, particularly VEGF (new blood vessel formation), fibroblast activity (collagen production), and nitric oxide signaling

Tissue Cell 89, 102472